What is Modulim?
Modulim is a pioneer in optical imaging solutions, specifically leveraging spatial frequency domain imaging (SFDI) to provide clinicians with actionable data regarding compromised circulation. By utilizing advanced light-based technology, the company enables healthcare providers to assess tissue health and perfusion with unprecedented accuracy. This diagnostic precision is essential for managing complex conditions such as diabetic foot ulcers and peripheral artery disease, where early intervention is paramount to patient outcomes.
The company operates at the intersection of photonics and clinical diagnostics, occupying a high-barrier-to-entry niche that requires both deep technical expertise and rigorous regulatory compliance. Its market position is bolstered by a robust intellectual property portfolio and strategic partnerships with global leaders in photonics and venture capital, ensuring that its technology remains at the forefront of medical innovation.
How much funding has Modulim raised?
Modulim has raised a total of $12.7M across 5 funding rounds:
Angel/Seed
$500K
Private Equity
$2M
Series A
$2.9M
Series B
$7M
Debt
$350K
Angel/Seed (2016): $500K with participation from The Cove Fund
Private Equity (2017): $2M, investors not publicly disclosed
Series A (2017): $2.9M supported by Hamamatsu, Grey Sky Venture Partners, and Mitsubishi UFJ Capital Co, Ltd
Series B (2019): $7M, investors not publicly disclosed
Debt (2020): $350K backed by PPP
Key Investors in Modulim
Hamamatsu
Hamamatsu Photonics is a global leader in photonics technology, providing advanced imaging sensors and optical systems for medical and scientific applications.
Mitsubishi UFJ Capital Co, Ltd
A prominent venture capital firm that provides strategic access and financial support to companies targeting the Japanese market and beyond.
The Cove Fund
An investment group focused on fostering innovation and providing the necessary capital to help emerging companies achieve long-term stability and growth.
What's next for Modulim?
With the recent influx of capital, Modulim is well-positioned to accelerate its commercialization efforts and expand its clinical reach. The strategic focus will likely center on scaling the deployment of its imaging platforms across major hospital networks and research institutions. By leveraging the expertise of its diverse investor base, the company is poised to enhance its product pipeline and potentially explore new therapeutic applications for its SFDI technology.
As the healthcare industry continues to prioritize non-invasive, data-driven diagnostic solutions, Modulim's ability to provide real-time, objective assessments of tissue health will be a key driver of its future growth. The company's roadmap suggests a transition from early-stage development to a mature, enterprise-level provider of essential clinical infrastructure, setting the stage for sustained market leadership.
